The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
9 reports, 3 independent
Updated Sat 00:00
Mostly repetition
- Reports
- 9
- Developments
- 2
- Repetition
- 78%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Amgen Inc. trades on the NASDAQ stock exchange.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Joint drug trial success boosts Amgen stock.
- Amgen and Microsoft are top holdings in an ETF.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
Coverage
Newest first; wire copies grouped- fool.com
- aol.com
- yahoo.comFBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It
- yahoo.com
- yahoo.com
- yahoo.com